Depomed (NASDAQ:DEPO) is headquartered in the United States and focuses on developing products for pain and diseases of the central nervous system.
Insider selling during the last 30 days
Here is a table of Depomed's insider activity during the last 30 days.
|Name||Title||Trade Date||Shares Sold||Rule 10b5-1||Current Ownership||Decrease In Ownership|
|Thadd Vargas||SVP||March 14||63,869||No||14,079 shares||81.9%|
|Matthew Gosling||SVP||March 14||21,875||No||11,396 shares||65.7%|
|James Schoeneck||CEO||March 14||17,000||No||96,306 shares||15.0%|
There have been 102,744 shares sold by insiders during the last 30 days.
Insider selling by calendar month
Here is a table of Depomed's insider activity by calendar month.
|Month||Insider selling / shares||Insider buying / shares|
There have been 138,015 shares sold, and there have been 27,000 shares purchased by insiders since January 2013. The month of March 2014 has seen the most insider selling.
Depomed reported the full-year 2013 financial results on March 12 with the following highlights:
|Net income||$43.3 million|
The three insiders sold their shares after these results.
Depomed's 2014 guidance is as follows:
|Product sales||$115-$125 million|
|Total revenues||$200-$215 million|
(Source: Earnings release)
Depomed has four own approved products, and several partner product candidates in the various stages of development.
On March 12, Depomed announced that the U.S. Food and Drug Administration approved Mallinckrodt plc's (NYSE:MNK) New Drug Application (NDA) for Xartemis XR. The NDA approval triggered a $10 million milestone payment to Depomed under Depomed's license agreement with Mallinckrodt.
|Qtrly Rev Growth (yoy):||0.53||0.05||2.21||2.46|
|PEG (5 yr expected):||-6.10||-0.24||N/A||0.43|
Depomed has the second-lowest insider ownership among these four companies.
Here is a table of these competitors' insider activities during the last six months.
|Company||Insider buying / shares||Insider selling / shares|
Only Depomed has seen intensive insider selling during the last 30 days.
There have been three different insiders selling Depomed, and there have not been any insiders buying Depomed during the last 30 days. All three of these insiders decreased their holdings by more than 10%. Depomed has an insider ownership of 0.40%.
There are three analyst buy ratings, one neutral rating, and zero sell ratings with an average price target of $11.63. Before going short Depomed, I would like to get a bearish confirmation from the Point and Figure chart. The two main reasons for the proposed short entry are bearish analyst price targets, and the intensive insider-selling activity.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.